Carlsmed Announces first corra™ personalized Cervical Plating Procedure

Carlsmed (Nasdaq: CARL) announced the first personalized cervical plating procedure using the corra™ Cervical Plating System on Feb. 18, 2026.

Rhea-AI Summary

Carlsmed (Nasdaq: CARL) announced the first personalized cervical plating procedure using the corra™ Cervical Plating System on Feb. 18, 2026.

The procedure, performed by Dr. Aaron Clark at UCSF, begins a clinical evaluation ahead of a planned commercial launch of corra™ later in 2026 and highlights integration with aprevo® planning and interbody devices.

Positive

• Completed first personalized corra™ cervical plating procedure on Feb. 18, 2026
• Clinical evaluation initiated at UCSF to inform product refinement
• corra™ integrates with aprevo® planning and interbody devices for patient-specific fit

Negative

• No published clinical outcomes yet; data will inform further refinement
• Commercial launch only anticipated later in 2026, timing remains uncertain

Argus Feb 19 session

+5.57% close to close Open Argus

Details

News Market Reaction – CARL

In the Feb 19 session, CARL gained 5.57%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. A strong positive reaction aligns with Car...

Analysis

The stock moved +5.6% in the session following this news. A strong positive reaction aligns with Carlsmed’s pattern of favorable responses to product and data milestones, such as earlier revenue and clinical updates. However, shares remained well below the 52-week high and the 200-day MA of $13.25, underscoring that the stock had been under technical pressure. Investors monitoring sustainability would typically watch subsequent clinical evaluation data, commercialization progress for cervical solutions, and upcoming 2025 earnings disclosures.

Historical Context

5 past events · Latest: Feb 11

5 events

1. Feb 11

   Earnings date set

   24h Move

   -5.8%

   Announcement of date for Q4 and full-year 2025 financial results release.

2. Feb 10

   New lumbar procedure

   24h Move

   -0.1%

   First aprevo® lumbar bi-lateral posterior fusion procedure at University of Colorado Hospital.

3. Jan 12

   Prelim 2025 revenue

   24h Move

   +13.8%

   Preliminary Q4 and full-year 2025 revenue with strong year-over-year growth and user expansion.

4. Jan 06

   2-year lumbar data

   24h Move

   +2.9%

   Peer-reviewed data showing reduced 2-year mechanical-complication revision rates versus conventional implants.

5. Dec 16

   Conference participation

   24h Move

   +0.0%

   Planned presentation and one-on-one investor meetings at a major healthcare conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

anterior cervical discectomy and fusion, acdf, biomechanics, digital surgery ecosystem

4 terms

anterior cervical discectomy and fusion medical

"precise alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures."

A surgical procedure that removes a damaged disc from the front of the neck and secures the two neighboring vertebrae together using a bone graft or implant to restore stability and relieve nerve pressure. Investors care because the operation drives demand for spinal implants, surgical tools and hospital services, and changes in procedure rates, device approvals, reimbursement or complication profiles can materially affect medical device makers, hospitals and insurers.

acdf medical

"alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures."

Anterior cervical discectomy and fusion (ACDF) is a surgical procedure to remove a damaged disc from the neck and join the adjacent vertebrae with bone graft or implants so the spine becomes stable. For investors, ACDF matters because demand for the surgery drives sales of medical devices, implants and related services—think of it as replacing a worn hinge and locking it in place, which affects revenues for companies that make the parts and tools used.

biomechanics medical

"This precision reinforces confidence in the biomechanics of each patient’s construct"

Biomechanics is the study of how forces and motion affect living bodies and body parts, applying basic physics to understand how tissues, joints, muscles, and devices move and bear load. For investors, biomechanics matters because it underpins the safety, effectiveness and competitive advantage of medical devices, implants, wearables and rehabilitation products—think of it as testing whether a bridge design will hold up under traffic before building it, which affects market adoption, regulatory approval and liability.

digital surgery ecosystem technical

"Utilizing Carlsmed’s digital surgery ecosystem, key anatomical aspects including"

A digital surgery ecosystem is a connected set of software, devices, data platforms and services that support surgical care — from planning and imaging to robot-assisted procedures and post-operative monitoring. For investors it matters because it turns isolated tools into recurring-revenue platforms and data assets, similar to how a smartphone app marketplace creates ongoing customer engagement and monetization opportunities, affecting growth, margins and regulatory risk for companies involved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the first personalized cervical plating procedure using the corra™ Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (UCSF), represents an important milestone as the Company prepares for the planned commercial launch of the corra™ system later this year.

“We’re excited to expand our personalized cervical offerings following the recent launch of our aprevo® Cervical Interbody System,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “This first procedure and the commencement of the clinical evaluation is an important step in validating our technology in a real-world setting. We developed corra™ to address unmet needs in cervical spine surgery, and we remain committed to delivering solutions designed to support surgeons, improve alignment precision and enhance patient outcomes through truly personalized design.”

The corra™ Cervical Plating System is designed to stabilize the cervical spine during fusion procedures using patient-specific plates tailored to each individual’s anatomy and surgical plan. Utilizing Carlsmed’s digital surgery ecosystem, key anatomical aspects including screw positioning and plate curvature are tailored pre-operatively to each vertebral level, helping support consistent fixation and precise alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures. When used in conjunction with the aprevo® cervical planning and interbody fusion devices, the corra™ Personalized Plating System can provide anatomical fit and fixation for patients.

“Cervical plates play a critical role in stabilizing fusion constructs, and extending personalization to cervical fixation can enable more precise plate positioning and screw trajectory,” said Dr. Aaron Clark of UCSF. “Designing each plate around patient-specific anatomy and alignment objectives has the potential to reduce intraoperative contouring and support more accurate execution of the preoperative plan. This precision reinforces confidence in the biomechanics of each patient’s construct and may help mitigate risks associated with adjacent-level stress that can contribute to postoperative symptoms and revision surgery following ACDF procedures.”

Data from the clinical evaluation will inform continued product refinement as Carlsmed prepares for broader market introduction. The Company expects to conduct additional evaluations in the coming months and anticipates commercial launch later this year.

About Carlsmed 
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about the timing of the commercial launch of the Company’s corra™ system, the potential of the Company’s products, the ability of the Company’s products to improve patient outcomes, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations 
Caroline Corner, PhD
IR@Carlsmed.com 

Media 
LeAnn Burton 
Senior Director Brand Marketing 
LBurton@Carlsmed.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Carlsmed (CARL) announce about the corra™ Cervical Plating System on Feb. 18, 2026?

Carlsmed announced the first personalized cervical plating procedure using corra™ on Feb. 18, 2026. According to the company, the procedure at UCSF begins a clinical evaluation ahead of a planned commercial launch later in 2026.

Who performed the first corra™ personalized cervical plating procedure for CARL and where?

Dr. Aaron Clark performed the first corra™ procedure at UCSF. According to the company, this clinical evaluation is intended to validate the technology in a real-world surgical setting.

How does the corra™ Cervical Plating System work with aprevo® for CARL patients?

corra™ uses patient-specific plates tailored to anatomy and surgical plans when paired with aprevo®. According to the company, screw positioning and plate curvature are tailored pre-operatively for precise ACDF fixation.

When does Carlsmed (CARL) plan to commercially launch the corra™ system?

Carlsmed anticipates a commercial launch of corra™ later in 2026. According to the company, additional clinical evaluations are planned in the coming months to inform product refinement before broader introduction.

What potential surgical benefits does corra™ offer for ACDF procedures according to CARL?

corra™ aims to improve alignment precision and reduce intraoperative contouring for ACDF procedures. According to the company, patient-specific plate design may support more accurate execution of preoperative plans and fixation consistency.

Will there be clinical data available immediately after the first corra™ procedure for CARL investors?

Not immediately—data from the clinical evaluation will guide product refinement and are forthcoming. According to the company, additional evaluations will be conducted in the coming months prior to broader market introduction.